

Maura Arosio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9090554/publications.pdf>

Version: 2024-02-01

233
papers

6,996
citations

46918

47
h-index

71532

76
g-index

247
all docs

247
docs citations

247
times ranked

5179
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical, Biochemical, and Morphological Correlates in Patients Bearing Growth Hormone-Secreting Pituitary Tumors with or without Constitutively Active Adenylyl Cyclase. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 71, 1421-1426.	1.8	284
2	SARS-CoV-2-related atypical thyroiditis. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 739-741.	5.5	225
3	Gamma-Knife Radiosurgery in Acromegaly: A 4-Year Follow-Up Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3105-3112.	1.8	198
4	Cortisol Secretion in Patients With Type 2 Diabetes: Relationship with chronic complications. <i>Diabetes Care</i> , 2007, 30, 83-88.	4.3	196
5	Predictors of morbidity and mortality in acromegaly: an Italian survey. <i>European Journal of Endocrinology</i> , 2012, 167, 189-198.	1.9	189
6	Long-Term Follow-Up in Adrenal Incidentalomas: An Italian Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 827-834.	1.8	180
7	Beneficial Metabolic Effects of Prompt Surgical Treatment in Patients with an Adrenal Incidentaloma Causing Biochemical Hypercortisolism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2736-2745.	1.8	171
8	Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case-control study in hospitalized patients. <i>European Journal of Endocrinology</i> , 2005, 153, 837-844.	1.9	160
9	Subclinical Hypercortisolism among Outpatients Referred for Osteoporosis. <i>Annals of Internal Medicine</i> , 2007, 147, 541.	2.0	140
10	Bone Mineral Density, Prevalence of Vertebral Fractures, and Bone Quality in Patients with Adrenal Incidentalomas with and without Subclinical Hypercortisolism: An Italian Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3207-3214.	1.8	140
11	Stimulatory Effects of Ghrelin on Circulating Somatostatin and Pancreatic Polypeptide Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 701-704.	1.8	135
12	Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. <i>European Journal of Endocrinology</i> , 2004, 151, 173-178.	1.9	127
13	Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: A multicenter longitudinal study. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 1816-1821.	3.1	109
14	Recombinant Human GH Replacement Therapy and Thyroid Function in a Large Group of Adult GH-Deficient Patients: When Does <sc></sc>-T₄ Therapy Become Mandatory?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 2042-2045.	1.8	108
15	Diverging Association of Reduced Glomerular Filtration Rate and Albuminuria With Coronary and Noncoronary Events in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 143-149.	4.3	107
16	Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. <i>Journal of Endocrinological Investigation</i> , 1997, 20, 537-546.	1.8	105
17	Prevalence of thyroid diseases in patients with acromegaly: results of an Italian Multi-center Study. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 240-245.	1.8	105
18	Effects of Modified Sham Feeding on Ghrelin Levels in Healthy Human Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5101-5104.	1.8	104

#	ARTICLE	IF	CITATIONS
19	Morphological Studies on Mixed Growth Hormone (GH)- and Prolactin (PRL)-Secreting Human Pituitary Adenomas. Coexistence of GH and PRL in the Same Secretory Granule*. Journal of Clinical Endocrinology and Metabolism, 1986, 62, 1093-1100.	1.8	102
20	Mutation of Somatostatin Receptor Type 5 in an Acromegalic Patient Resistant to Somatostatin Analog Treatment. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3809-3814.	1.8	99
21	Effect of Recombinant Human Growth Hormone (GH) Replacement on the Hypothalamic-Pituitary-Adrenal Axis in Adult GH-Deficient Patients. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5397-5401.	1.8	91
22	Comparison between Six-Year Therapy with Long-Acting Somatostatin Analogs and Successful Surgery in Acromegaly: Effects on Cardiovascular Risk Factors. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 121-128.	1.8	88
23	Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH). European Journal of Endocrinology, 2018, 178, 23-32.	1.9	84
24	Thyrotropin-Secreting Pituitary Adenomas: Outcome of Pituitary Surgery and Irradiation. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2069-2076.	1.8	79
25	Effects of treatment with octreotide in acromegalic patients—a multicenter Italian study. European Journal of Endocrinology, 1995, 133, 430-439.	1.9	78
26	Circulating ghrelin levels in basal conditions and during glucose tolerance test in acromegalic patients. European Journal of Endocrinology, 2002, 147, 189-194.	1.9	76
27	Ectopic Acromegaly. Endocrinology and Metabolism Clinics of North America, 1992, 21, 575-595.	1.2	75
28	Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clinical Endocrinology, 2010, 73, 161-166.	1.2	74
29	Screening of Cushing's Syndrome in Outpatients with Type 2 Diabetes: Results of a Prospective Multicentric Study in Italy. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3467-3475.	1.8	70
30	First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clinical Endocrinology, 2006, 64, 342-351.	1.2	69
31	In Vivo Detection of Somatostatin Receptors in Patients with Functionless Pituitary Adenomas by Means of a Radioiodinated Analog of Somatostatin ([¹²³ I]SDZ 204-090)*. Journal of Clinical Endocrinology and Metabolism, 1991, 73, 850-856.	1.8	68
32	Effects of two different somatostatin analogs on glucose tolerance in acromegaly. Journal of Endocrinological Investigation, 2002, 25, 502-507.	1.8	66
33	Post-surgical hypocortisolism after removal of an adrenal incidentaloma: is it predictable by an accurate endocrinological work-up before surgery?. European Journal of Endocrinology, 2010, 162, 91-99.	1.9	66
34	Efficacy of radiotherapy in normalizing serum IGF-I, acid-labile subunit (ALS) and IGFBP-3 levels in acromegaly. Clinical Endocrinology, 2001, 55, 183-189.	1.2	65
35	Efficacy and tolerability of gamma knife radiosurgery in acromegaly: a 10-year follow-up study. Clinical Endocrinology, 2009, 71, 846-852.	1.2	65
36	Accuracy of several parameters of hypothalamic-pituitary-adrenal axis activity in predicting before surgery the metabolic effects of the removal of an adrenal incidentaloma. European Journal of Endocrinology, 2010, 163, 925-935.	1.9	65

#	ARTICLE	IF	CITATIONS
37	Efficacy of a slow-release formulation of lanreotide (Autogel®120Âmg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. <i>Clinical Endocrinology</i> , 2007, 67, 512-519.	1.2	64
38	Glycoprotein Hormone $\hat{\pm}$ -Subunit Response to Growth Hormone(GH)-Releasing Hormone in Patients with Active Acromegaly $\hat{\text{A}}$ - Evidence for $\hat{\pm}$ -Subunit and GH Coexistence in the Same Tumoral Cell*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1985, 61, 541-546.	1.8	62
39	Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. <i>European Journal of Endocrinology</i> , 2003, 148, 39-43.	1.9	62
40	Acromegaly is associated with increased cancer risk: a survey in Italy. <i>Endocrine-Related Cancer</i> , 2017, 24, 495-504.	1.6	61
41	Eugonadal male patients with adrenal incidentalomas and subclinical hypercortisolism have increased rate of vertebral fractures. <i>Clinical Endocrinology</i> , 2009, 70, 208-213.	1.2	60
42	Long-Term Evaluation of Postoperative Acromegalic Patients in Remission with Previous and Newly Proposed Criteria. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1377-1382.	1.8	58
43	Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status. <i>Clinical Endocrinology</i> , 2003, 58, 725-731.	1.2	55
44	Recombinant hGH replacement therapy and the hypothalamus-pituitary-thyroid axis in children with GH deficiency: when should we be concerned about the occurrence of central hypothyroidism?. <i>Clinical Endocrinology</i> , 2003, 59, 806-810.	1.2	53
45	High mortality within 90 days of diagnosis in patients with Cushingâ€™s syndrome: results from the ERCUSYN registry. <i>European Journal of Endocrinology</i> , 2019, 181, 461-472.	1.9	53
46	Cardiovascular events in patients with mild autonomous cortisol secretion: analysis with artificial neural networks. <i>European Journal of Endocrinology</i> , 2017, 177, 73-83.	1.9	52
47	Clinical use of pre- and postsurgical evaluation of abnormal GH responses in acromegaly. <i>Journal of Neurosurgery</i> , 1983, 59, 402-408.	0.9	51
48	Protective Effect of Denosumab on Bone in Older Women with Primary Hyperparathyroidism. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 518-524.	1.3	51
49	Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. <i>European Journal of Endocrinology</i> , 2008, 158, 19-25.	1.9	47
50	LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. <i>Atherosclerosis</i> , 2000, 151, 551-557.	0.4	46
51	Circulating ghrelin levels in patients with inflammatory bowel disease. <i>Gut</i> , 2006, 55, 432-433.	6.1	46
52	Lack of Desensitization of Adenomatous Somatotrophs to Growth-Hormone Releasing Hormone in Acromegaly*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1987, 64, 585-591.	1.8	45
53	Hypothalamic-pituitary-adrenal activity in type 2 diabetes mellitus: role of autonomic imbalance. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 1135-1140.	1.5	44
54	Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naïve patients with acromegaly. <i>Journal of Endocrinological Investigation</i> , 2009, 32, 202-209.	1.8	43

#	ARTICLE	IF	CITATIONS
55	Growth Hormone Receptor Variants and Response to Pegvisomant in Monotherapy or in Combination with Somatostatin Analogs in Acromegalic Patients: A Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E165-E172.	1.8	41
56	Long-term monitoring of insulin sensitivity in growth hormone-deficient adults on substitutive recombinant human growth hormone therapy. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 740-743.	1.5	39
57	Gs protein mutations and pituitary tumors: Functional correlates and possible therapeutic implications. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 117-119.	1.5	37
58	Diagnostic Value of the Acid-Labile Subunit in Acromegaly: Evaluation in Comparison with Insulin-Like Growth Factor (IGF) I, and IGF-Binding Protein-1, -2, and -3. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1091-1098.	1.8	37
59	Blood pressure-independent cardiac hypertrophy in acromegalic patients. <i>Journal of Hypertension</i> , 1999, 17, 1965-1969.	0.3	36
60	Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 533-538.	1.8	36
61	Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2000, 108, 486-492.	0.6	35
62	Resistant hypertension in patients with type 2 diabetes. <i>Journal of Hypertension</i> , 2014, 32, 2401-2410.	0.3	35
63	Improved diastolic function in type 2 diabetes after a six month liraglutide treatment. <i>Diabetes Research and Clinical Practice</i> , 2016, 118, 21-28.	1.1	34
64	Prevalence of GH deficiency in cured acromegalic patients: impact of different previous treatments. <i>European Journal of Endocrinology</i> , 2009, 161, 37-42.	1.9	31
65	Diagnostic Value of the Acid-Labile Subunit in Acromegaly: Evaluation in Comparison with Insulin-Like Growth Factor (IGF) I, and IGF-Binding Protein-1, -2, and -3. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1091-1098.	1.8	31
66	Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. <i>PLoS ONE</i> , 2015, 10, e0125512.	1.1	30
67	Adequacy of current postglucose GH nadir limit (<math>< 1 \mu\text{g/l}</math>) to define long-lasting remission of acromegalic disease. <i>Clinical Endocrinology</i> , 2007, 66, 538-542.	1.2	29
68	Prediction of Vertebral Fractures in Patients With Monolateral Adrenal Incidentalomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2768-2775.	1.8	28
69	Approach to hyponatremia according to the clinical setting: Consensus statement from the Italian Society of Endocrinology (SIE), Italian Society of Nephrology (SIN), and Italian Association of Medical Oncology (AIOM). <i>Journal of Endocrinological Investigation</i> , 2018, 41, 3-19.	1.8	28
70	Adrenal Insufficiency at the Time of COVID-19: A Retrospective Study in Patients Referring to a Tertiary Center. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1354-e1361.	1.8	28
71	Circulating levels of growth hormone, insulin-like growth factor-I and prolactin in normal, growth retarded and anencephalic human fetuses. <i>Journal of Endocrinological Investigation</i> , 1995, 18, 346-353.	1.8	27
72	Growth hormone receptor polymorphism in acromegaly: effects on metabolic phenotype. <i>Clinical Endocrinology</i> , 2010, 72, 661-667.	1.2	27

#	ARTICLE	IF	CITATIONS
73	Follow-up of patients with adrenal incidentaloma, in accordance with the European society of endocrinology guidelines: Could we be safe?. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 331-333.	1.8	27
74	Natural history of Rathke's cleft cysts: A retrospective analysis of a two centres experience. <i>Clinical Endocrinology</i> , 2018, 89, 178-186.	1.2	27
75	Bone involvement in young adults with cystic fibrosis awaiting lung transplantation for end-stage respiratory failure. <i>Osteoporosis International</i> , 2019, 30, 1255-1263.	1.3	27
76	Minding the gap between cortisol levels measured with second-generation assays and current diagnostic thresholds for the diagnosis of adrenal insufficiency: a single-center experience. <i>Hormones</i> , 2020, 19, 425-431.	0.9	26
77	Cardiovascular mortality in patients with subclinical Cushing. <i>Annales D'Endocrinologie</i> , 2018, 79, 149-152.	0.6	25
78	Progressive bone impairment with age and pubertal development in neurofibromatosis type I. <i>Archives of Osteoporosis</i> , 2018, 13, 93.	1.0	25
79	Circulating adiponectin levels and cardiovascular risk factors in acromegalic patients. <i>European Journal of Endocrinology</i> , 2004, 150, 663-669.	1.9	24
80	GH Replacement Improves Quality of Life and Metabolic Parameters in Cured Acromegalic Patients with Growth Hormone Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3983-3988.	1.8	24
81	Clinically Nonfunctioning Pituitary Incidentalomas: Characteristics and Natural History. <i>Neuroendocrinology</i> , 2020, 110, 595-603.	1.2	24
82	Growth Hormone and Prolactin Secretion in Acromegaly: Correlations Between Hormonal Dynamics and Immunocytochemical Findings*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1988, 67, 1195-1204.	1.8	23
83	Peripheral insulin-like factor 3 concentrations are reduced in men with type 2 diabetes mellitus: effect of glycemic control and visceral adiposity on Leydig cell function. <i>European Journal of Endocrinology</i> , 2009, 161, 853-859.	1.9	23
84	Influence of the d3GH receptor polymorphism on the metabolic and biochemical phenotype of GH-deficient adults at baseline and during short- and long-term recombinant human GH replacement therapy. <i>European Journal of Endocrinology</i> , 2010, 163, 361-368.	1.9	22
85	A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment. <i>International Journal of Cancer</i> , 2018, 142, 1842-1852.	2.3	22
86	Single-Molecule Microscopy Reveals Dynamic FLNA Interactions Governing SSTR2 Clustering and Internalization. <i>Endocrinology</i> , 2018, 159, 2953-2965.	1.4	22
87	cAMP/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells. <i>Cancer Letters</i> , 2018, 435, 101-109.	3.2	21
88	COVID-19 in Cushing disease: experience of a single tertiary centre in Lombardy. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1335-1336.	1.8	21
89	Ultrasound-Guided Laser Thermal Ablation for Parathyroid Adenomas: Analysis of Three Cases with a Three-Year Follow-Up. <i>Hormone Research in Paediatrics</i> , 2006, 65, 231-234.	0.8	19
90	Screening for ACTH-dependent hypercortisolism in patients affected with pituitary incidentaloma. <i>European Journal of Endocrinology</i> , 2015, 172, 363-369.	1.9	19

#	ARTICLE	IF	CITATIONS
91	Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function. <i>Clinical Therapeutics</i> , 2017, 39, 159-169.	1.1	19
92	Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity. <i>Pituitary</i> , 2019, 22, 552-560.	1.6	19
93	Ghrelin administration affects circulating pituitary and gastro-entero-pancreatic hormones in acromegaly. <i>European Journal of Endocrinology</i> , 2004, 150, 27-32.	1.9	18
94	Adrenal morpho-functional alterations in patients with acromegaly. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 602-606.	1.8	18
95	Endocrine and metabolic assessment in adults with Langerhans cell histiocytosis. <i>European Journal of Internal Medicine</i> , 2018, 51, 61-67.	1.0	18
96	Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.8	18
97	Delayed closure of epiphyseal cartilages induced by the aromatase inhibitor anastrozole. Would it help short children grow up?. <i>Journal of Endocrinological Investigation</i> , 2000, 23, 721-723.	1.8	17
98	Predictability of hypoadrenalism occurrence and duration after adrenalectomy for ACTH-independent hypercortisolism. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 485-493.	1.8	17
99	Vertebral Fractures Associated with Spinal Sagittal Imbalance and Quality of Life in Acromegaly: A Radiographic Study with EOS 2D/3D Technology. <i>Neuroendocrinology</i> , 2021, 111, 775-785.	1.2	17
100	ACUTE HEPATITIS AFTER TREATMENT OF ACROMEGALY WITH OCTREOTIDE. <i>Lancet, The</i> , 1988, 332, 1498.	6.3	16
101	Mental Health in Patients With Adrenal Incidentalomas: Is There a Relation With Different Degrees of Cortisol Secretion?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e130-e139.	1.8	16
102	Evaluation of cardiac structure by echoreflectivity analysis in acromegaly: effects of treatment. <i>European Journal of Endocrinology</i> , 2004, 151, 179-186.	1.9	15
103	Effectiveness of long-term rosiglitazone administration in patients with Cushing's disease. <i>Clinical Endocrinology</i> , 2005, 63, 118-119.	1.2	15
104	Diagnostic features and outcome of surgical therapy of acromegalic patients: Experience of the last three decades. <i>Hormones</i> , 2014, 13, 95-103.	0.9	15
105	Role of UGT1A1 and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patients. <i>European Journal of Endocrinology</i> , 2014, 170, 247-254.	1.9	15
106	Indication to dynamic and invasive testing in Cushing's disease according to different neuroradiological findings. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 629-637.	1.8	15
107	Mutations in the Alpha Subunit of the Stimulatory Regulatory Protein of Adenylyl Cyclase (Gs) in Human GH-Secreting Pituitary Adenomas. <i>Pathology Research and Practice</i> , 1991, 187, 567-570.	1.0	14
108	Increased glucose-dependent insulinotropic polypeptide (GIP) secretion in acromegaly. <i>European Journal of Endocrinology</i> , 2001, 145, R1-R4.	1.9	14

#	ARTICLE	IF	CITATIONS
109	Somatostatin analogs regulate tumor corticotrophs growth by reducing ERK1/2 activity. <i>Molecular and Cellular Endocrinology</i> , 2019, 483, 31-38.	1.6	14
110	ESE audit on management of adult growth hormone deficiency in clinical practice. <i>European Journal of Endocrinology</i> , 2021, 184, 323-334.	1.9	14
111	Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors. <i>Endocrine-Related Cancer</i> , 2019, 26, R95-R108.	1.6	14
112	Modifications in Serum Growth Hormone Concentration Induced by Sulpiride in Acromegalic Patients Pretreated with Dopamine, Bromocriptine, and Metergoline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1980, 51, 454-461.	1.8	13
113	Mosaicism for GNAS methylation defects associated with pseudohypoparathyroidism type 1B arose in early post-zygotic phases. <i>Clinical Epigenetics</i> , 2018, 10, 16.	1.8	13
114	Trabecular Bone Score (TBS) and Bone Metabolism in Patients Affected with Type 1 Neurofibromatosis (NF1). <i>Calcified Tissue International</i> , 2019, 104, 207-213.	1.5	13
115	Cytoskeleton Protein Filamin A Is Required for Efficient Somatostatin Receptor Type 2 Internalization and Recycling through Rab5 and Rab4 Sorting Endosomes in Tumor Somatotroph Cells. <i>Neuroendocrinology</i> , 2020, 110, 642-652.	1.2	13
116	Growth hormone therapy at the time of Covid-19 pandemic: adherence and drug supply issues. <i>European Journal of Endocrinology</i> , 2020, 183, L13-L15.	1.9	13
117	Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19 hospitalized patients. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13753.	1.7	13
118	Acromegaly and thymic hyperplasia: a case report. <i>Journal of Endocrinological Investigation</i> , 1990, 13, 931-935.	1.8	12
119	Size heterogeneity of circulating growth hormone in acromegaly. "Big-Big" GH forms are associated with inappropriately low IGF-I levels. <i>European Journal of Endocrinology</i> , 1991, 125, 150-159.	1.9	12
120	Differential transduction of dopamine signal in different subtypes of human growth hormone-secreting adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 78, 411-417.	1.8	12
121	Detection of small bowel tumors by videocapsule endoscopy in patients with acromegaly. <i>Journal of Endocrinological Investigation</i> , 2009, 32, 495-500.	1.8	12
122	TNM 8th edition in thyroid cancer staging: is there an improvement in predicting recurrence?. <i>Endocrine-Related Cancer</i> , 2020, 27, 325-336.	1.6	12
123	GH Response to Oral Glucose Tolerance Test: A Comparison between Patients with Acromegaly and Other Pituitary Disorders. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E83-E88.	1.8	11
124	Improved Molecular Diagnosis of McCune-Albright Syndrome and Bone Fibrous Dysplasia by Digital PCR. <i>Frontiers in Genetics</i> , 2019, 10, 862.	1.1	11
125	Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas. <i>Hormones and Cancer</i> , 2019, 10, 120-127.	4.9	11
126	Spine Bone Texture Assessed by Trabecular Bone Score in Active and Controlled Acromegaly: A Prospective Study. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab090.	0.1	11

#	ARTICLE	IF	CITATIONS
127	Genetic Profiling of a Cohort of Italian Patients with ACTH-Secreting Pituitary Tumors and Characterization of a Novel USP8 Gene Variant. <i>Cancers</i> , 2021, 13, 4022.	1.7	11
128	USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs. <i>Endocrine-Related Cancer</i> , 2021, 28, 573-582.	1.6	11
129	Adrenalectomy Improves Blood Pressure and Metabolic Control in Patients With Possible Autonomous Cortisol Secretion: Results of a RCT. <i>Frontiers in Endocrinology</i> , 2022, 13, .	1.5	11
130	Effects of propranolol on GH responsiveness to repeated GH-releasing hormone stimulations in normal subjects. <i>European Journal of Endocrinology</i> , 1990, 122, 735-739.	1.9	10
131	Effects of 12-month GH treatment on bone metabolism and bone mineral density in adults with adult-onset GH deficiency. <i>Journal of Endocrinological Investigation</i> , 2001, 24, 224-230.	1.8	10
132	Recovery of Adrenal Function after Pituitary Surgery in Patients with Cushing Disease: Persistent Remission or Recurrence?. <i>Neuroendocrinology</i> , 2019, 108, 211-218.	1.2	10
133	Determinants of outcome of transsphenoidal surgery for Cushing disease in a single-centre series. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 631-639.	1.8	10
134	Tolvaptan in the Management of Acute Euvolemic Hyponatremia After Transsphenoidal Surgery: A Retrospective Single-Center Analysis. <i>Frontiers in Endocrinology</i> , 2021, 12, 689887.	1.5	10
135	Hyperandrogenism by Liquid Chromatography Tandem Mass Spectrometry in PCOS: Focus on Testosterone and Androstenedione. <i>Journal of Clinical Medicine</i> , 2021, 10, 119.	1.0	10
136	Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life. <i>Endocrine</i> , 2022, 77, 510-518.	1.1	10
137	Stem Cells in Pituitary Tumors: Experimental Evidence Supporting Their Existence and Their Role in Tumor Clinical Behavior. <i>Frontiers in Endocrinology</i> , 2019, 10, 745.	1.5	9
138	Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on AKT Phosphorylation and Cell Proliferation in Pituitary Tumors. <i>Neuroendocrinology</i> , 2021, 111, 568-579.	1.2	9
139	Reevaluation of Acromegalic Patients in Long-Term Remission according to Newly Proposed Consensus Criteria for Control of Disease. <i>International Journal of Endocrinology</i> , 2014, 2014, 1-8.	0.6	8
140	Cofilin is a cAMP effector in mediating actin cytoskeleton reorganization and steroidogenesis in mouse and human adrenocortical tumor cells. <i>Cancer Letters</i> , 2017, 406, 54-63.	3.2	8
141	A Rare SPRY4 Gene Mutation Is Associated With Anosmia and Adult-Onset Isolated Hypogonadotropic Hypogonadism. <i>Frontiers in Endocrinology</i> , 2019, 10, 781.	1.5	8
142	Cushing's disease: a prospective case-control study of health-related quality of life and cognitive status before and after surgery. <i>Journal of Neurosurgery</i> , 2019, , 1-11.	0.9	8
143	Elevated circulating somatostatin levels in acromegaly. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 499-502.	1.8	7
144	Denosumab or oral bisphosphonates in primary osteoporosis: a "cereal-life" study. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 1005-1013.	1.8	7

#	ARTICLE	IF	CITATIONS
145	The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells. <i>Cancer Letters</i> , 2021, 497, 77-88.	3.2	7
146	A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation. <i>Frontiers in Endocrinology</i> , 2020, 11, 611752.	1.5	7
147	Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence. <i>European Journal of Endocrinology</i> , 2021, 185, 387-396.	1.9	7
148	Procoagulant Imbalance in Klinefelter Syndrome Assessed by Thrombin Generation Assay and Whole-Blood Thromboelastometry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1660-e1672.	1.8	7
149	Human pancreatic growth hormone-releasing factor (hpGRF-44) in acromegaly before and after adenomectomy. Modifications induced by somatostatin (GHRH) infusion. <i>Journal of Endocrinological Investigation</i> , 1985, 8, 449-453.	1.8	6
150	Long-term effects of radiotherapy on cardiovascular risk factors in acromegaly. <i>European Journal of Endocrinology</i> , 2011, 164, 675-684.	1.9	6
151	Central hypogonadism in Klinefelter syndrome: report of two cases and review of the literature. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 459-470.	1.8	6
152	Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation. <i>Molecular and Cellular Endocrinology</i> , 2019, 495, 110519.	1.6	5
153	Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells. <i>Molecular and Cellular Endocrinology</i> , 2021, 524, 111159.	1.6	5
154	Case Report: A Challenging Localization of a Pulmonary Ectopic ACTH-Secreting Tumor in a Patient With Severe Cushing's Syndrome. <i>Frontiers in Endocrinology</i> , 2021, 12, 687539.	1.5	5
155	Influence of biochemical diagnosis of growth hormone deficiency on replacement therapy response and retesting results at adult height. <i>Scientific Reports</i> , 2021, 11, 14553.	1.6	5
156	Clinical and hormonal findings in patients presenting with high IGF-1 and growth hormone suppression after oral glucose load: a retrospective cohort study. <i>European Journal of Endocrinology</i> , 2021, 185, 289-297.	1.9	5
157	A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy. <i>Cancers</i> , 2021, 13, 5831.	1.7	5
158	Association of GNAS imprinting defects and deletions of chromosome 2 in two patients: clues explaining phenotypic heterogeneity in pseudohypoparathyroidism type 1B/iPPSD3. <i>Clinical Epigenetics</i> , 2019, 11, 3.	1.8	4
159	Post-surgical Thyroid Bed Pyoderma Gangrenosum Mimicking Recurrent Papillary Thyroid Carcinoma. <i>Frontiers in Endocrinology</i> , 2019, 10, 253.	1.5	4
160	Gender Identity Fluctuation in a Genetic Female with Late-Onset, Non-Classical Congenital Adrenal Hyperplasia. <i>Archives of Sexual Behavior</i> , 2019, 48, 1265-1268.	1.2	4
161	2q37 Deletions in Patients With an Albright Hereditary Osteodystrophy Phenotype and PTH Resistance. <i>Frontiers in Endocrinology</i> , 2019, 10, 604.	1.5	4
162	Safety and effectiveness of Omnitrope® in patients with growth hormone deficiency: snapshot analysis of PATRO Adults study in the Italian population. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 327-337.	1.8	4

#	ARTICLE	IF	CITATIONS
163	Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion. <i>Molecular and Cellular Endocrinology</i> , 2021, 520, 111092.	1.6	4
164	Novel Pathogenetic Variants in PTHLH and TRPS1 Genes Causing Syndromic Brachydactyly. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 465-474.	3.1	4
165	Long-term monitoring of rec-GH treatment by serial determination of serum aminoterminal propeptide of type III procollagen in children and adults with GH deficiency. <i>Journal of Endocrinological Investigation</i> , 1999, 22, 169-175.	1.8	3
166	Impact of IGF(CA)19 gene polymorphism on the metabolic response to GH therapy in adult GH-deficient patients. <i>European Journal of Endocrinology</i> , 2014, 170, 273-281.	1.9	3
167	Radioiodine ablation with 1,850ÂMBq in association with rhTSH in patients with differentiated thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 709-714.	1.8	3
168	Genetic profiling of a cohort of Italian patients with ACTH-secreting pituitary tumors and characterization of a novel USP8 gene variant. <i>Endocrine Abstracts</i> , 0, , .	0.0	3
169	Evaluation of procoagulant imbalance in Cushingâ€™s syndrome after short- and long-term remission of disease. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 9-16.	1.8	3
170	P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs. <i>Cancers</i> , 2022, 14, 2455.	1.7	3
171	Mesencephalic and bulbar reticular formation influences on somatosensory transmission through the thalamus. <i>Electroencephalography and Clinical Neurophysiology</i> , 1982, 53, 338-342.	0.3	2
172	Human growth hormone treatment and Creutzfeldt-Jakob disease. <i>Journal of Endocrinological Investigation</i> , 1986, 9, 439-439.	1.8	2
173	Effects of consecutive doses of GHRH on OH secretion. <i>Clinical Endocrinology</i> , 1991, 35, 187-188.	1.2	2
174	Role of <sc>IGF</sc>1â€(<sc>CA</sc>) ₁₉ promoter microsatellite in the clinical presentation of acromegaly. <i>European Journal of Clinical Investigation</i> , 2014, 44, 1222-1229.	1.7	2
175	Usefulness of non-stimulated copeptin in the diagnosis of diabetes insipidus after pituitary surgery. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2315-2317.	1.8	2
176	The hypersecreting somatotroph: functional and morphological aspects. , 1989, , 411-421.		2
177	Comparison between the efficacy of the Anti-BAFF monoclonal antibody belimumab vs methylprednisolone in active moderate-severe gravesâ€™ orbitopathy: an interim analysis. <i>Endocrine Abstracts</i> , 0, , .	0.0	2
178	Adrenal Insufficiency at the Time of COVID-19: A Retrospective Study in Patients Referring to a Tertiary Centre. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
179	Therapy for the syndromes of GH excess. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 36-43.	1.8	2
180	Case Report: A Novel ARMC5 Germline Mutation in a Patient with Primary Bilateral Macronodular Adrenal Hyperplasia and Hypogammaglobulinemia. <i>Frontiers in Genetics</i> , 2022, 13, 834067.	1.1	2

#	ARTICLE	IF	CITATIONS
181	Lack of effect of hexarelin on TRH-induced TSH response in normal adult man. Journal of Endocrinological Investigation, 1998, 21, 239-244.	1.8	1
182	Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience. Journal of Endocrinological Investigation, 2021, 44, 2593-2599.	1.8	1
183	Evolution of SARS-CoV-2 related atypical thyroiditis. Endocrine Abstracts, 0, , .	0.0	1
184	Bisphosphonates after Denosumab withdrawal reduce the vertebral fractures incidence. Endocrine Abstracts, 0, , .	0.0	1
185	Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion. Endocrine Abstracts, 0, , .	0.0	1
186	Treatment of acromegalic osteopathy in the real-life clinical practice: The baac (bone active drugs in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.0	1
187	SUN-362 Bone Involvement in Adult Patients Affected with Ehlers-Danlos Syndromes. Journal of the Endocrine Society, 2020, 4, .	0.1	1
188	Case Report: Unusual Presentations of Loss-of-Function Mutations of the Calcium-Sensing Receptor. Frontiers in Medicine, 2021, 8, 809067.	1.2	1
189	Acute effects of a single administration of dexamethasone on basal and growth hormone-releasing hormone stimulated GH secretion in acromegaly. Clinical Endocrinology, 1994, 40, 187-191.	1.2	0
190	La radiochirurgia nella patologia tumorale ipofisaria. L Endocrinologo, 2007, 8, 85-93.	0.0	0
191	Effects of adrenalectomy on arterial hypertension, glucose and lipid metabolism in patients with mild autonomous cortisol secretion: preliminary results of a Randomized Clinical Trial. Endocrine Abstracts, 0, , .	0.0	0
192	Novel insight into ACTH-secreting pituitary tumors biological behavior: hormone secretion and cell proliferation modulation by Ubiquitin Specific Peptidase 8 inhibitor RA-9. Endocrine Abstracts, 0, , .	0.0	0
193	Metabolic and Inflammation markers in patients with mild autonomous cortisol secretion: preliminary results of a Randomized Clinical Trial. Endocrine Abstracts, 0, , .	0.0	0
194	Case Report: Late-Onset Congenital Adrenal Hyperplasia and Acute Covid-19 Infection in a Pregnant Woman: Multidisciplinary Management. Frontiers in Endocrinology, 2020, 11, 602535.	1.5	0
195	Accuracy of Several Parameters of Hypothalamic-Pituitary-Adrenal Axis Activity in Predicting the Improvement of the Metabolic Consequences after Recovery from Adrenal Subclinical Hypercortisolism.. , 2010, , P2-672-P2-672.		0
196	Demographic Data, Co-Morbidities, Malignancies and Mortality from the First Large-Scale Italian Study on Acromegaly.. , 2010, , P3-253-P3-253.		0
197	Associated Hypersecretion of Anterior Pituitary Hormones other than Growth Hormone in Acromegaly. , 1987, , 179-191.		0
198	SAT-566 Cofilin Is a Mediator of RET-Promoted Medullary Thyroid Carcinoma Cell Migration, Invasion and Proliferation. Journal of the Endocrine Society, 2019, 3, .	0.1	0

#	ARTICLE	IF	CITATIONS
199	MON-465 SST2 Trafficking Through The Cytoskeleton: Role Of Scaffolding Proteins Filamin A And β -arrestin 2. Journal of the Endocrine Society, 2019, 3, .	0.1	0
200	Novel insight into ACTH-secreting pituitary tumors biological behavior: somatostatin receptor type 5 (SST5) modulation by ubiquitin specific peptidase 8 (USP8). Endocrine Abstracts, 0, , .	0.0	0
201	Diagnostic accuracy of copeptin in the diagnosis of diabetes insipidus after pituitary surgery. Endocrine Abstracts, 0, , .	0.0	0
202	The role of filamin A (FLNA) in the regulation of IGF2/IGF1R pathway in adrenocortical carcinomas. Endocrine Abstracts, 0, , .	0.0	0
203	Assessment of biochemical hyperandrogenism in PCOs by liquid chromatography tandem mass spectrometry using a multisteroid kit: focus on testosterone and androstenedione. Endocrine Abstracts, 0, , .	0.0	0
204	Characteristics and natural history of a large cohort of non-functioning pituitary incidentalomas: a two-centers study. Endocrine Abstracts, 0, , .	0.0	0
205	Somatostatin receptor type 2 trafficking through the cytoskeleton: role of scaffolding proteins Filamin A and β -arrestin 2. Endocrine Abstracts, 0, , .	0.0	0
206	Retrospective analysis of the efficacy of three different dose regimens of rituximab in patients with active moderate-severe graves' orbitopathy. Endocrine Abstracts, 0, , .	0.0	0
207	Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation. Endocrine Abstracts, 0, , .	0.0	0
208	β -arrestin 2 expression is required for dopamine receptor type 2 (DRD2) inhibitory effects on Akt phosphorylation and cell proliferation in PRL-secreting and non functioning pituitary tumors. Endocrine Abstracts, 0, , .	0.0	0
209	Somatostatin receptor type 5 modulation by Filamin A in ACTH-secreting pituitary tumors. Endocrine Abstracts, 0, , .	0.0	0
210	European observational study of ketoconazole for endogenous cushing's syndrome in collaboration with European registry on cushing's syndrome ERCUSYN: PASS ketoconazole study design and rationale. Endocrine Abstracts, 0, , .	0.0	0
211	Remission rate of acromegaly after somatostatin analogs withdrawal: an update. Endocrine Abstracts, 0, , .	0.0	0
212	The prevalence of macro TSH in patients with subclinical hypothyroidism: experience of a single centre. Endocrine Abstracts, 0, , .	0.0	0
213	Telemedicine in the management of acromegalic patients. Endocrine Abstracts, 0, , .	0.0	0
214	Role of invasive and non-invasive diagnostic tests in differential diagnosis of ACTH-dependent Cushing's syndrome. Endocrine Abstracts, 0, , .	0.0	0
215	SAT-312 Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on Akt Phosphorylation and Cell Proliferation in Pituitary Tumors. Journal of the Endocrine Society, 2020, 4, .	0.1	0
216	Effects of adrenalectomy on arterial hypertension in patients with adrenal subclinical hypercortisolism: Preliminary results of a randomized clinical trial. Endocrine Abstracts, 0, , .	0.0	0

#	ARTICLE	IF	CITATIONS
217	Clinical and genetic characterization of two cases of central hypogonadism in Klinefelter syndrome. Endocrine Abstracts, 0, , .	0.0	0
218	Controversies in the spectrum of GH-IGF-I axis disorders requiring replacement therapy. Endocrine Abstracts, 0, , .	0.0	0
219	Radiofrequency Echographic Multi Spectrometry (REMS) evaluation in patients with primary osteoporosis and primary hyperparathyroidism. Endocrine Abstracts, 0, , .	0.0	0
220	Use of tolvaptan in acute post-surgical hyponatremia in patients with pituitary diseases. Endocrine Abstracts, 0, , .	0.0	0
221	Deletion of chromosome 1q24-1q32 and combined pituitary hormone deficiency type 4: Insight into the challenges of genotype-phenotype correlation. Endocrine Abstracts, 0, , .	0.0	0
222	Micromegaly or acromegaly? A retrospective longitudinal study on clinical aspects and comorbidities in a large cohort of patients referred to a single tertiary center. Endocrine Abstracts, 0, , .	0.0	0
223	A novel mechanism regulating dopamine receptor type 2 (DRD2) signal transduction in PRL- and ACTH-secreting pituitary tumoral cells: The role of cAMP/PKA-induced filamin A (FLNA) phosphorylation in the control of responsiveness to DRD2 agonist. Endocrine Abstracts, 0, , .	0.0	0
224	TNM 8th edition in thyroid cancer staging: Is there an improvement in predicting recurrence?. Endocrine Abstracts, 0, , .	0.0	0
225	Assessment of hypercoagulability in patients with cushing syndrome before and after surgical cure. Endocrine Abstracts, 0, , .	0.0	0
226	Coagulation abnormalities in patients with klinefelter syndrome compared to age-matched healthy controls: Cross-sectional assessment by thrombin generation test. Endocrine Abstracts, 0, , .	0.0	0
227	Baseline IGF-I values influence the effect of rhGH therapy on fat mass: Short, medium and long term study on adults with GH deficiency. Endocrine Abstracts, 0, , .	0.0	0
228	Association between sagittal spine imbalance and radiological vertebral fractures in acromegaly: Does it reflect a pathophysiological link?. Endocrine Abstracts, 0, , .	0.0	0
229	NGS sequencing proves as a powerful method to perform differential diagnosis in patients with inactivating PTH/PTHrP signaling disorders (iPPSD). Endocrine Abstracts, 0, , .	0.0	0
230	Role of NGS in the diagnostic work-up of pituitary tumors and "incidental findings". Endocrine Abstracts, 0, , .	0.0	0
231	Adrenal insufficiency at the time of COVID-19: A retrospective study. Endocrine Abstracts, 0, , .	0.0	0
232	SUN-213 The Role of Filamin A (FLNA) in the Regulation of Insulin-Like Growth Factor System in Adrenocortical Carcinomas. Journal of the Endocrine Society, 2020, 4, .	0.1	0
233	A case of testicular atrophy associated with cystic fibrosis. Endocrinology, Diabetes and Metabolism Case Reports, 2020, 2020, .	0.2	0